Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells under Long-Term watch: will the benefits last?

NCT ID NCT07683897

Disease control Sponsor: Vittoria Biotherapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study follows people who have already been treated with Senza5 CART5, a personalized cell therapy that uses a patient's own immune cells engineered to target cancer. The goal is to track long-term safety and how well the treatment continues to control the disease. Participants will be monitored for any side effects related to the therapy over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Senza5 CART5 (a type of engineered immune cell therapy)
What this could lead to
If successful, this follow-up could show that Senza5 CART5 provides lasting disease control with an acceptable long-term safety profile.
What could go wrong
This is a small, non-randomized follow-up study, so results may not apply to all patients. Long-term side effects or loss of effectiveness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2041

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants treated with Senza5 CART5 who have met all eligibility criteria and provided written informed consent for LTFU-Viper 101 (or have written informed consent from their parent\[s\]/legal guardian\[s\] and have provided assent, as applicable).

Ages

18 to 100 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants meeting the following criteria are eligible for trial participation: * Provision of written informed consent by the participant or provision of written informed consent from the participant's parent\[s\]/legal guardian\[s\] and provision of assent from the participant, as applicable * Treated with Senza5 CART5 in a Vittoria BioTherapeutics sponsored clinical trial * Able to comply with trial requirements Exclusion Criteria: * There are no exclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Participants treated with SENZA5 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Participants treated with SENZA5

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.